Clinical Trial Title Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Trial Status Closed to Enrollment
Start Date 08/17/2010
Location randall-childrens-hospital-at-legacy-emanuel
Trial Type Pediatric Cancer (Oncology)
Specific Condition Acute Lymphoblastic Leukemia (ALL) Standard Risk B-Precursor
Description This partially randomized phase III trial studies different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
Eligibility Criteria Patients must be enrolled on COG AALL08B1 (Classification Study) prior to enrollment on COG AALL0932

Age: >365 days and <10 years of age

Must have an initial white blood cell count <50,000/uL

Newly diagnosed Standard Risk B-precursor ALL

Patients with Down syndrome are also eligible

Patients must have not received any prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously, with the exception of steroids and intrathecal cytarabine for the current diagnosis of ALL

Patients with CNS3 status are not eligible for this study; are eligible for COG High Risk AALL1131 Study

Patients with testicular leukemia are not eligible for this study
IRB Number

Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.
Principal Investigator Janice Olson, MD
Contact Name Children's Cancer and Blood Disorders Program
Contact Phone (503) 276-9300
Contact Fax
Contact E-Mail